Latest News

Tovecimig plus paclitaxel yielded a median OS of 8.9 months vs 9.4 months with control in second-line biliary tract cancer in the phase 2/3 COMPANION-002 trial.

The MagnetisMM-5 study remains ongoing to assess the key secondary end point of overall survival among those with relapsed/refractory multiple myeloma.

According to Asfar Azmi, PhD, results from the study showed that the PCNA inhibitor AOH1996 was synergistic with KRAS inhibitors of all classes.

Experts outline technological advances, treatment de-escalation strategies, and lifestyle factors that may impact treatment for head and neck cancers.

Isaac Allen, PhD, analyzed how post-diagnostic lifestyle behaviors may affect oncological outcomes, including patient health-seeking behavior influences.

Asfar Azmi, PhD, discussed a poster from the AACR Annual Meeting that investigated the NAMPT inhibitor RPT-E-037 and the pan-RAS inhibitor daraxonrasib in pancreatic cancer.

A data monitoring committee recommended the halt for futility of the phase 3 FLASH2 trial evaluating synthetic hypericin in cutaneous T-cell lymphoma.

iSCIB1+ continues to be studied in the SCOPE trial for patients with advanced melanoma.

A young father faces a potential lymphoma diagnosis, revealing how medical language, restraint, and rapid coordination reshape care and ease uncertainty.

A total of 48.0% of patients treated with duvelisib experienced a response, 33.3% of whom experienced a complete response.

CancerNetwork, AJMC, and Pharmacy Times are producing The Bispecifics Network, where Ralph V. Boccia, MD, FACP, breaks down the importance of this initiative.

The new guidelines address 11 key clinical questions for optimizing communication between clinicians and patients with cancer.

Data from the phase 1/2 CARDINAL trial support the breakthrough therapy designation for TERN-701 in this chronic myeloid leukemia population.

Experts discussed a case study involving a patient with multiple myeloma who developed CAR T-cell–related lymphomagenesis in the gastrointestinal tract.

In vivo CAR T-cell engineering represents a fundamental rethinking of how cellular therapies are produced and delivered.

Read this to learn 3 things you should know about the first-line treatment of mTNBC with TROP2-directed ADCs.

The safety profile of zocilurtatug pelitecan among patients with extrapulmonary neuroendocrine carcinomas was consistent with prior reports in SCLC.

Molecular testing and multidisciplinary care play a vital role in treating rare sarcomas, according to Steven Bialick, DO.

New trials reshape gastroesophageal adenocarcinoma care with durvalumab‑FLOT, HER2, and CLDN18.2 targets, plus practical toxicity tips.

Data presented at the 2026 AACR Annual Meeting highlighted promising therapeutic approaches in diseases such as NSCLC and oral premalignant lesions.

Penetration of molecular testing for non–small cell lung cancer in the US is not at 100%, according to Lyudmila Bazhenova, MD, FASCO.

Recently, conservative management has grown in popularity, especially among older patients and those with higher neighborhood-level socioeconomic status.

A panel of experts gathered to discuss the landscape of care in early-relapse multiple myeloma, new phase 3 data, and select patient cases.

The conditional marketing authorization for tovorafenib in pediatric patients with low-grade glioma harboring a BRAF alteration is based on data from the FIREFLY-1 trial.

Patrick A. Kenney, MD; and David A. Braun, MD, PhD, discussed parameters they use to determine a patient’s eligibility for cytoreductive nephrectomy.

According to Diane Simeone, MD, parallel investments in early screening and novel therapeutics can improve survival rates in pancreatic cancer.